Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort
Abstract
Aims: Eplerenone and spironolactone differ in pharmacological profile, but whether this translates into meaningful differences in clinical outcomes in heart failure (HF) remains uncertain. We compared the two agents in a registry-based new-user cohort with serial laboratory data.
Methods and results: In this observational cohort study, adults with a first HF diagnosis in Stockholm County (2005–2019) who were prescribed either spironolactone or eplerenone within 6 months were identified from linked Swedish registries with individual-level laboratory results. Follow-up was analysed under an intention-to-treat principle. Outcomes included all-cause mortality, HF hospitalization, kidney function decline, and hyperkalaemia. The main analysis used multivariable Cox regression. Several sensitivity analyses were performed, including propensity score matching. Of 75 565 patients with new-onset HF, 12 046 initiated a mineralocorticoid receptor antagonist (11 039 spironolactone; 1007 eplerenone). Eplerenone was associated with lower all-cause mortality (hazard ratio 0.78, 95% confidence interval 0.62–0.98), a lower risk of more than 50% decline in estimated glomerular filtration rate (eGFR) (0.69, 0.54–0.88), sustained eGFR below 30 mL/min/1.73 m2 (0.69, 0.49–0.95), a composite kidney outcome (0.71, 0.56–0.90), and hyperkalaemia of 5.5 mmol/L or above (0.76, 0.60–0.96). The cause-specific hazard for HF hospitalization was higher with eplerenone (1.29, 1.11–1.51) but attenuated to 0.99 (0.87–1.12) when death was treated as a competing risk. Findings were robust across sensitivity analyses.
Conclusion: Compared with spironolactone, eplerenone was associated with lower all-cause mortality and lower risks of kidney function decline and mild hyperkalaemia. These observational findings warrant confirmation in randomized comparisons.
Related
- Association Between the Naples Prognostic Score and In-Hospital Mortality in Patients with Type 2 Cardiorenal Syndrome: A Retrospective Cohort Study
- Association between the non-HDL-c to HDL-c ratio and mortality risk in cardiorenal syndrome : A population-based study from 1999 to 2018 NHANES
- Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease
- Cirrhotic Cardiomyopathy and Related Cardiocirculatory Dysfunction: A Systematic Review of Therapeutic Responses and Cardiorenal Outcomes
- Network and pairwise meta-analysis of the effects of novel hypoglycemic agents on cardiorenal outcomes in patients with type 2 diabetes and heart failure
BibTeX
@article{warnberg2026eplerenone,
title = {{Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort}},
author = {Karl Wärnberg and Carl Haggård and Karin Bergen and Henrik Falhammar and Buster Mannheimer and Krister Lindmark},
journal = {European Heart Journal. Cardiovascular Pharmacotherapy},
year = {2026},
month = sep,
doi = {10.1093/ehjcvp/pvag064},
url = {https://doi.org/10.1093/ehjcvp/pvag064},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort
AU - Karl Wärnberg
AU - Carl Haggård
AU - Karin Bergen
AU - Henrik Falhammar
AU - Buster Mannheimer
AU - Krister Lindmark
PY - 2026
DA - 2026/09/10
JO - European Heart Journal. Cardiovascular Pharmacotherapy
DO - 10.1093/ehjcvp/pvag064
UR - https://doi.org/10.1093/ehjcvp/pvag064
AB - Aims: Eplerenone and spironolactone differ in pharmacological profile, but whether this translates into meaningful differences in clinical outcomes in heart failure (HF) remains uncertain. We compared the two agents in a registry-based new-user cohort with serial laboratory data. Methods and results: In this observational cohort study, adults with a first HF diagnosis in Stockholm County (2005–2019) who were prescribed either spironolactone or eplerenone within 6 months were identified from linked Swedish registries with individual-level laboratory results. Follow-up was analysed under an intention-to-treat principle. Outcomes included all-cause mortality, HF hospitalization, kidney function decline, and hyperkalaemia. The main analysis used multivariable Cox regression. Several sensitivity analyses were performed, including propensity score matching. Of 75 565 patients with new-onset HF, 12 046 initiated a mineralocorticoid receptor antagonist (11 039 spironolactone; 1007 eplerenone). Eplerenone was associated with lower all-cause mortality (hazard ratio 0.78, 95% confidence interval 0.62–0.98), a lower risk of more than 50% decline in estimated glomerular filtration rate (eGFR) (0.69, 0.54–0.88), sustained eGFR below 30 mL/min/1.73 m2 (0.69, 0.49–0.95), a composite kidney outcome (0.71, 0.56–0.90), and hyperkalaemia of 5.5 mmol/L or above (0.76, 0.60–0.96). The cause-specific hazard for HF hospitalization was higher with eplerenone (1.29, 1.11–1.51) but attenuated to 0.99 (0.87–1.12) when death was treated as a competing risk. Findings were robust across sensitivity analyses. Conclusion: Compared with spironolactone, eplerenone was associated with lower all-cause mortality and lower risks of kidney function decline and mild hyperkalaemia. These observational findings warrant confirmation in randomized comparisons.
SN - 2055-6837
SN - 2055-6845
ER -